BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 27042161)

  • 1. Basigin-2 upregulated by receptor activator of NF-κB ligand enhances lung cancer-induced osteolytic lesions.
    Liao CG; Yao L; Xie W; Liu L; Wu SD; Lu N; Huang JG; Kong LM; Zhang HL
    Cancer Cell Int; 2016; 16():28. PubMed ID: 27042161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147.
    Rucci N; Millimaggi D; Mari M; Del Fattore A; Bologna M; Teti A; Angelucci A; Dolo V
    Cancer Res; 2010 Aug; 70(15):6150-60. PubMed ID: 20631064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts.
    Kanekura T; Chen X; Kanzaki T
    Int J Cancer; 2002 Jun; 99(4):520-8. PubMed ID: 11992541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
    Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
    Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TIE1 promotes cervical cancer progression via Basigin-matrix metalloproteinase axis.
    Liu P; Xie L; Wu Q; Huang L; Liu X; Li W; Cai J; Wang Z; Yang P; Cai L
    Int J Biol Sci; 2024; 20(6):2297-2309. PubMed ID: 38617545
    [No Abstract]   [Full Text] [Related]  

  • 6. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
    Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
    Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
    Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
    Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
    Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
    J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
    Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
    Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
    Shimo T; Kubota S; Yoshioka N; Ibaragi S; Isowa S; Eguchi T; Sasaki A; Takigawa M
    J Bone Miner Res; 2006 Jul; 21(7):1045-59. PubMed ID: 16813525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer.
    Kim HJ; Park J; Lee SK; Kim KR; Park KK; Chung WY
    J Pathol; 2015 Dec; 237(4):520-31. PubMed ID: 26239696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
    Liu Y; Zhang RX; Yuan W; Chen HQ; Tian DD; Li H; Jiang X; Deng ZL; Wang Y
    Cell Physiol Biochem; 2018; 45(5):1759-1771. PubMed ID: 29495003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment.
    Huang L; Cheng YY; Chow LT; Zheng MH; Kumta SM
    Mol Pathol; 2003 Apr; 56(2):116-20. PubMed ID: 12665629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of an orally active small-molecule inhibitor of RANKL in bone metastasis.
    Nakai Y; Okamoto K; Terashima A; Ehata S; Nishida J; Imamura T; Ono T; Takayanagi H
    Bone Res; 2019; 7():1. PubMed ID: 30622830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
    J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel interaction between calcium-modulating cyclophilin ligand and Basigin regulates calcium signaling and matrix metalloproteinase activities in human melanoma cells.
    Long T; Su J; Tang W; Luo Z; Liu S; Liu Z; Zhou H; Qi M; Zeng W; Zhang J; Chen X
    Cancer Lett; 2013 Oct; 339(1):93-101. PubMed ID: 23879967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF.
    Park BK; Zhang H; Zeng Q; Dai J; Keller ET; Giordano T; Gu K; Shah V; Pei L; Zarbo RJ; McCauley L; Shi S; Chen S; Wang CY
    Nat Med; 2007 Jan; 13(1):62-9. PubMed ID: 17159986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.